Becton, Dickinson and Company (NYSE:BDX) Issues FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of 12.350-12.650 for the period, compared to the consensus EPS estimate of 14.810. The company issued revenue guidance of -.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $210.45 on Monday. The company has a fifty day simple moving average of $199.83 and a 200-day simple moving average of $192.36. The firm has a market capitalization of $59.96 billion, a price-to-earnings ratio of 36.10, a PEG ratio of 2.32 and a beta of 0.25. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $235.34.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.09. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BDX shares. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a report on Wednesday, January 28th. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Citigroup assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 3rd. They set a “buy” rating and a $233.00 price target on the stock. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $213.36.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 2,463 shares of company stock valued at $501,530 over the last 90 days. 0.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BDX. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. Parvin Asset Management LLC grew its position in Becton, Dickinson and Company by 4.3% during the 3rd quarter. Parvin Asset Management LLC now owns 4,055 shares of the medical instruments supplier’s stock worth $759,000 after purchasing an additional 168 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in Becton, Dickinson and Company by 5.2% in the second quarter. Geneos Wealth Management Inc. now owns 3,437 shares of the medical instruments supplier’s stock valued at $592,000 after purchasing an additional 169 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $33,000. Finally, Diversify Wealth Management LLC boosted its stake in shares of Becton, Dickinson and Company by 8.1% during the second quarter. Diversify Wealth Management LLC now owns 2,425 shares of the medical instruments supplier’s stock worth $418,000 after buying an additional 181 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.